Last reviewed · How we verify
Fasenra®
Fasenra is a monoclonal antibody that binds to and depletes interleukin-5 receptor alpha (IL-5Rα) on eosinophils, reducing eosinophil levels in the blood and tissues.
Fasenra is a monoclonal antibody that binds to and depletes interleukin-5 receptor alpha (IL-5Rα) on eosinophils, reducing eosinophil levels in the blood and tissues. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (CRSwNP).
At a glance
| Generic name | Fasenra® |
|---|---|
| Also known as | benralizumab |
| Sponsor | AstraZeneca |
| Drug class | IL-5 receptor antagonist monoclonal antibody |
| Target | IL-5Rα (interleukin-5 receptor alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
By targeting IL-5Rα, Fasenra prevents the binding of interleukin-5 (IL-5) to its receptor, which is critical for eosinophil survival, recruitment, and activation. This leads to selective depletion of eosinophils, thereby reducing eosinophil-mediated inflammation in conditions like severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA).
Approved indications
- Severe eosinophilic asthma
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Chronic rhinosinusitis with nasal polyps (CRSwNP)
Common side effects
- Headache
- Pharyngitis
- Pyrexia
- Injection site reactions
Key clinical trials
- Fasenra Pediatric Japan Post-Marketing Study(PMS)
- A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab (PHASE4)
- FAsenra Safety Trial in India (PHASE4)
- Interaction Between Benralizumab and Basophils in Eosinophilic Asthma
- RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
- Similarities and Differences of Biological Therapies for Severe Asthma.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fasenra® CI brief — competitive landscape report
- Fasenra® updates RSS · CI watch RSS
- AstraZeneca portfolio CI